Ne Rx Pharma

NeRx Pharma is a biotechnology company dedicated to developing a new class of targeted cancer therapies that inhibit DNA repair mechanisms. The company's primary focus is on the development of small molecule inhibitors of Replication Protein A (RPA), a critical protein involved in DNA replication and repair. By targeting RPA, NeRx aims to overcome resistance to traditional chemotherapy and radiation, particularly in difficult-to-treat cancers like non-small cell lung cancer and ovarian cancer. Their lead candidate, NERX-329, is designed to selectively disrupt the DNA damage response in cancer cells while sparing healthy tissue.